Physician profile
Sharon Lilly
NPI 1265469852
$2,049.31
in general payments reported to CMS, 2019-2025
23 companies · $320 in 2025
The $320 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $230 · 2021: $525 · 2022: $279 · 2023: $82.46 · 2024: $17.64 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $286.44 | 2019-2025 | Onyda Xr |
| Glaxosmithkline, LLC. | $220.91 | 2019-2022 | |
| Pfizer INC. | $210.10 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $203.49 | 2021-2025 | Qelbree, Qelbree |
| Sanofi Pasteur INC. | $169.46 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $167.62 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $162.93 | 2020-2021 | |
| Neos Therapeutics, LP | $88.37 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $71.51 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $56.73 | 2021 | |
| Corium, LLC | $55.19 | 2025 | Azstarys |
| Merck Sharp & Dohme LLC | $49.11 | 2021-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi-Aventis U.S. LLC | $42.97 | 2025 | |
| Cranial Technologies, INC | $40.55 | 2024-2025 | Doc Band |
| Sobi, INC | $35.06 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.02 | 2019 | |
| Seqirus USA INC | $31.39 | 2022 | |
| Hologic Sales and Service, LLC | $29.82 | 2021 | |
| Shire North American Group INC | $28.06 | 2019 | |
| Genentech USA, INC. | $22.75 | 2019-2020 | |
| Cipher Pharmaceuticals US LLC | $16.16 | 2025 | Spinosad, Natroba |
| Organon LLC | $15.85 | 2025 | |
| Sarepta Therapeutics, INC. | $12.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Lilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.